U.S. Markets open in 6 hrs 37 mins
  • S&P Futures

    3,913.50
    -2.75 (-0.07%)
     
  • Dow Futures

    31,463.00
    -24.00 (-0.08%)
     
  • Nasdaq Futures

    12,136.50
    -4.00 (-0.03%)
     
  • Russell 2000 Futures

    1,760.30
    -1.40 (-0.08%)
     
  • Crude Oil

    107.46
    -0.16 (-0.15%)
     
  • Gold

    1,837.70
    +7.40 (+0.40%)
     
  • Silver

    21.42
    +0.29 (+1.37%)
     
  • EUR/USD

    1.0565
    +0.0007 (+0.0634%)
     
  • 10-Yr Bond

    3.1250
    0.0000 (0.00%)
     
  • Vix

    27.23
    -1.82 (-6.27%)
     
  • GBP/USD

    1.2279
    +0.0009 (+0.0774%)
     
  • USD/JPY

    135.1350
    -0.0350 (-0.0259%)
     
  • BTC-USD

    21,212.84
    -260.73 (-1.21%)
     
  • CMC Crypto 200

    462.63
    +8.73 (+1.92%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,871.27
    +379.30 (+1.43%)
     

Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic malignancies.

  • CTX130 was well tolerated across all dose levels. There were no cases of Graft versus Host Disease (GvHD), no dose-limiting toxicities (DLTs), and no instances of tumor lysis syndrome (TLS).

  • Needham notes that 95% of beta-thalassemia (TDT) achieved sustained transfusion independence (TI), with the remaining two showing a significantly reduced transfusion burden.

  • An overall response rate (ORR) of 70% with a 30% complete response (CR) rate was reported in patients at dose levels≥3 (300M and 900M cells).

  • Chardan has updated its model, increasing POS for exa-cel in TDT and SCD to 75% from 65% and 60%, respectively.

  • Needham believes the impressive and durable efficacy observed with CTX001 makes it a competitive therapeutic even if Bluebird Bio Inc's (NASDAQ: BLUE) beti-cel enters the market first.

  • Read Next: FDA Advisory Committee Backs Bluebird Bio's Blood Disorder Gene Therapy.

  • HC Wainwright says beti-cels' efficacy and safety profile are comparable to CTX001, although the modalities are different.

  • Chardan believes exa-cel is positioned to overtake beti-cel (given its lead in SCD and as BLUE has pulled out of Europe), betting on CRSP's partner Vertex Pharmaceuticals Inc's (NASDAQ: VRTX) global infrastructure.

  • Price Action: CRSP shares are down 13.5% at $55.15 during the market session on the last check Monday.

Latest Ratings for CRSP

Date

Firm

Action

From

To

Feb 2022

RBC Capital

Maintains

Sector Perform

Feb 2022

SVB Leerink

Maintains

Outperform

Dec 2021

Cowen & Co.

Initiates Coverage On

Market Perform

View More Analyst Ratings for CRSP

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.